NAGORSEN, DIRK,KUFER, PETER,ZUGMAIER, GERHARD,BAEUERLE, PATRICK
申请号:
HK13100007.6
公开号:
HK1172828B
申请日:
2013.01.02
申请国别(地区):
HK
年份:
2016
代理人:
摘要:
Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.